-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Benzinga·09/23/2026 12:14:06
Diffusion vocale
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.